Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 55,516	$ 36,632
Short-term investments – available for sale	306,563	118,853
Prepaid clinical trial and preclinical study costs	2,624	8,144
Prepaid expenses and other current assets	2,522	3,411
Total current assets	367,225	167,040
Right-of-use assets	1,126	1,418
Deferred financing costs	106	38
Deposits	33	33
Total assets	368,490	168,529
Current liabilities:
Accounts payable	7,512	8,529
Other accrued liabilities	11,299	13,114
Lease liability, current	324	304
Total current liabilities	19,135	21,947
Lease liability, net of current portion	936	1,260
Total long-term liabilities	936	1,260
Total liabilities	20,071	23,207
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022
Common stock, $0.00001 par value: 300,000,000 shares authorized at December 31, 2023 and 2022; 100,113,770 shares issued and outstanding at December 31, 2023 an 78,257,258 shares issued and outstanding at December 31, 2022	1	1
Treasury stock at cost, 2,193,251 shares at December 31, 2023 and 2022	(6,795)	(6,795)
Additional paid-in capital	733,546	445,267
Accumulated deficit	(377,944)	(292,049)
Accumulated other comprehensive loss	(389)	(1,102)
Total stockholders’ equity	348,419	145,322
Total liabilities and stockholders’ equity	$ 368,490	$ 168,529